Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Bisphophonates are the treatment of choice to prevent skeletal events in patients with multiple myeloma. Some preclinical studies suggested that bisphophonates can be useful as antitumor drugs in some malignancies. We conducted a controlled clinical trial to assess if zoledronic acid can have this clinical activity. Ninetyfour patients with previously untreated multiple myeloma were treated with a conventional chemotherapy program: cyclophosphamide, vincristine, melphalan, and prednisone (CVMP) and were randomized to received either zoledronic acid (4 mg, iv, every 28 d) or not (control group). The end-point of the present study was to assess improvement in outcome, measured by event-free survival (EFS) and overall survival (OS), and the second-end point was to confirm the efficacy in preventing skeletal events. In an intent-to-treat analysis, all patients were available for efficacy and toxicity. Median follow up was 49.6 mo (range: 34–72 mo). Five year actuarial curves showed that EFS was 80% in the zoledronic acid group, which was statistically different from 52% in the control group (p < 0.01). Actuarial 5 yr OS was 80% in the zoledronic acid arm, and 46% in the control group (p < 0.01). Sketeletal events were more frequent in the control group when compared to zoledronic acid. Toxicity was mild. We confirm the efficacy of zoledronic acid to prevent skeletal events, but we felt that we can demonstrate that zoledronic acid has a clinical antitumor effect measured from a increase in complete response rate and EFS and OS that were better when compared with the control group. We began a controlled clinical trial with modern treatment (including transplant procedures) in combination with zoledronic acid to define the role of zoledonic acid in this setting of patients.
- Smith A, et al. Diagnosis and management of multiple myeloma.Br J Haematol 2001;115:522–540. CrossRef
- Barosi G, et al. Management of multiple myeloma and related disorders.Haematologica 2004;89:717–741.
- Kyle R, Rajkumar SV. Multiple myeloma.N Engl J Med 2004;351:1860–1873. CrossRef
- Dimopoulus MA, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduced skeletal events.J Clin Oncol 1998;16:593–601.
- Terpos E, Dimopoulus MA. Myeloma bone disease. Patholphysiology and management.Ann Oncol 2005;16:1223–1231. CrossRef
- Shipman LM, Rogers MJ, Apperley JF, Graham GG, Croucher PJ. Bisphosphonates induce apoptosis in human myeloma cell lines. A novel anti-tumor activity.Br J Haematol 1997;98:665–672. CrossRef
- Diel IJ, Mundy GR. Bisphosphonates in the adjuvant treatment of cancer. Experimental evidence and first clinical results.Br J Cancer 2000;82:1381–1386.
- Buissier S, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion an early event to the formation of bone metastase.Cancer Res 2000;60:2949–2954.
- Green JR. Anti-tumor effect of bisphosphonates.Cancer 2002;97 (Suppl 2):840–847.
- Clezardin P. The anti-tumor potential of bisphosphonates.Sem Oncol 2002;29:33–42.
- Kunzman V, Bauer E, Furia J. Stimulation of gamma/delta T cells by amino-bisphosphonates and induction of antiplasma cells activity in multiple myeloma.Blood 2000;96:384–392.
- Berenson JR, et al. Zoledronic acid reduced skeletal-related events in patients with osteolytic metastases.Cancer 2001;91:1191–1200. CrossRef
- Alvarez E, et al. Properties of bisphosphonates in the 13762 rat mammary carcinoma-model of tumor-induced bone resorption.Clin Cancer Res 2003;9:5705–5713.
- Neville-Webbe HL, Holen I, Coleman RE. The anti-tumor effect of bisphosphonatesCancer Treat Rev 2002;28:305–319. CrossRef
- Green JR, Cl’ezardin P. Mechanisms of bisphosphonates effects on osteoclasts, tumor cell growth and metastasis.Am J Clin Oncol 2002;25(Suppl 6): 53–59.
- Swanson KM, Tung IZ, Wiemer AJ, Murthy S, Holl RJ. Potential mechanisms for the anti-myeloma properties of bissphosphonates.Proc Am Soc Oncol 2005;23 (Suppl 1), 581 (abstract 6582).
- Blad’e J, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoetic stem cells transplantation.Br J Haematol 1998;102:1115–1121. CrossRef
- Talavera A, et al. Treatment of multiple myeloma in advanced stages: cyclophosphamide, melphalan, vincristine, prednisone alternating with carmustine or epirubicin; versus cyclophosphamide, melphalan, vincristine and dexamethasone alternating with interferon alfa 2b.Cancer Res Ther Control 2000;10:273–278.
- Avil’es A, et al. Biological modifiers as cytoreductive therapy before stem cell transplant in previously untreated patients with multiple myeloma.Ann Oncol 2005;16:219–221. CrossRef
- Avilées A. et al. Novel therapy in multiple myeloma.Invest New Drugs 2005;23:412–415. CrossRef
- Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma
Volume 24, Issue 2 , pp 227-230
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press
- Additional Links
- Multiple myeloma
- zoledronic acid
- litic lesions
- Industry Sectors